Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 26 May 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Eosinophilic esophagitis is associated with IgG4 and not mediated by IgE

This month's Gastroenterology evaluates the roles of IgE and IgG4 in the development of eosinophilic esophagitis.

News image

Eosinophilic esophagitis is usually triggered by foods, by unclear mechanisms.

Dr Frederic Clayton and colleagues from Utah, USA evaluated the roles of IgE and IgG4 in the development of eosinophilic esophagitis.

The research team performed a prospective, randomized, double-blind, placebo-controlled trial of adults with eosinophilic esophagitis given an antibody against IgE or placebo every 2–4 weeks for 16 weeks, based on weight and serum level of IgE.

Endoscopy was performed, esophageal biopsy specimens were collected, and symptoms were assessed at baseline and at 16 weeks.

Maximum numbers of eosinophils/high-power field were determined.

Granular extracellular IgG4 was detected in biopsy specimens from 21 of 24 patients
Gastroenterology

Homogenates of esophageal biopsy specimens from 11 subjects with eosinophilic esophagitis and 8 without were assessed for IgM, IgA, and IgG subclasses.

In a retrospective analysis, the researchers performed immunofluorescence analysis of IgG4 in fixed esophageal tissues from 2 patients with eosinophilic esophagitis who underwent esophagectomy, and 47 consecutive autopsies.

The researchers also performed immunofluorescence analysis of IgG4 in esophageal mucosal biopsy specimens from 24 subjects with eosinophilic esophagitis, and 9 without.

Finally, sera were collected from 15 subjects with eosinophilic esophagitis and from 41 without (controls), and assayed for total and food-reactive IgG4.

The research team found that omalizumab did not alter symptoms of eosinophilic esophagitis or eosinophil counts in biopsy samples compared with placebo.

Homogenates of esophageal tissues from patients with eosinophilic esophagitis had a 45-fold increase in IgG4 compared with controls, but no significant increases in other IgG subclasses, IgM, or IgA.

Sparse stromal deposits resembling immune complexes were found in 2 of 5 eosinophilic esophagitis biopsy specimens based on ultrastructural analysis.

The team found that esophagectomy samples from 2 patients with eosinophilic esophagitis contained 180 and 300 IgG4 plasma cells/maximal high-power field, mainly in the deep lamina propria; these levels were greater than in tissues from controls.

Fibrosis essentially was exclusive to the lamina propria.

Granular extracellular IgG4 was detected in biopsy specimens from 21 of 24 patients with eosinophilic esophagitis, but in none of the specimens from 9 controls.

The researchers found that total serum level of IgG4 increased only slightly in patients with eosinophilic esophagitis, compared with controls.

Subjects with eosinophilic esophagitis had increased serum levels of IgG4 that reacted with milk, wheat, egg, and nuts—the 4 foods that most commonly trigger this condition.

Dr Clayton's team concludes, "In a prospective trial, omalizumab did not reduce symptoms of eosinophilic esophagitis or tissue eosinophil counts compared with placebo."

"This finding, along with observed granular deposits of IgG4, abundant IgG4-containing plasma cells, and serum levels of IgG4 reactive to specific foods, indicate that, in adults, eosinophilic esophagitis is IgG4-associated, and not an IgE-induced allergy."

Gastroenterol 2014: 147(3): 602–609
02 September 2014

Go to top of page Email this page Email this page to a colleague

 26 May 2016 
Direct-acting antivirals in Hep C cirrhosis
 26 May 2016 
Education booklet for colonoscopy bowel preparation
 26 May 2016 
Uncomplicated diverticulitis in outpatients
 25 May 2016 
Recurrence of Barrett’s after successful endoscopic therapy
 25 May 2016 
Preventing NSAID-associated GI toxicity
 25 May 2016 
PPIs and NSAID-induced small bowel injury
 24 May 2016 
Fecal inflammatory markers in Crohn's
 24 May 2016 
Depression and IBD recurrence
 24 May 2016 
New therapies for NASH
 23 May 2016 
Risk factors for peptic ulcer bleeding outcomes
 23 May 2016 
Liver transplantation for hepatocellular carcinoma
 23 May 2016 
Cancer after colectomy in IBD
 20 May 2016 
Biomarker for colorectal cancer diagnosis
 20 May 2016 
Prognostic score for hepatic venous outflow obstruction
 20 May 2016 
Treatment for uncomplicated acute diverticulitis
 19 May 2016 
Probiotics and H. pylori eradication
 19 May 2016 
Impaired skeletal health in atrophic gastritis
 19 May 2016 
Predicting outcome in ulcerative colitis
 18 May 2016 
Erectile dysfunction in IBD
 18 May 2016 
Surgical fundoplication for GERD 
 18 May 2016 
Acute GERD and esophageal histologic changes
 17 May 2016 
Vitamin D level and clinical status in IBD 
 17 May 2016 
Mucosal dysbiosis in Crohn's disease
 17 May 2016 
Inpatient costs for IBD and acute pancreatitis
 16 May 2016 
Outcomes of postcolonoscopy colorectal cancers
 16 May 2016 
C. difficile in ulcerative colitis patients
 16 May 2016 
Therapy for Crohn's in a Medicaid population
 13 May 2016 
Parkinson's disease and IBD
 13 May 2016 
Non-traditional heart disease risk factors in NAFLD
 13 May 2016 
Inactivated oral cholera vaccine
 12 May 2016 
Gestational diabetes mellitus and NAFLD
 12 May 2016 
Impact of Crohn's in the USA
 12 May 2016 
Ozanimod induction and ulcerative colitis
 11 May 2016 
Anti-TNF discontinuation in IBD
 11 May 2016 
Age and disease presentation with Crohn's disease
 11 May 2016 
Prognosis after colorectal cancer resection
 10 May 2016 
Gluten-free diet in patients with IBS-diarrhea
 10 May 2016 
Noninvasive test for IBD
 10 May 2016 
Digital health for gastroenterology
 09 May 2016 
Diarrheal infections in adults
 09 May 2016 
Quality improvement initiative and readmission for cirrhosis
 09 May 2016 
Coffee or tea and the risk of Barrett's
 06 May 2016 
Risk factors in peptic ulcer bleeding
 06 May 2016 
Recurrent pancreatitis after acute pancreatitis
 06 May 2016 
Managing acute lower GI bleeding
 05 May 2016 
Chemoradiotherapy vs chemotherapy for pancreatic cancer
 05 May 2016 
Genetics in early-early-onset IBD
 05 May 2016 
Reductions in quality of screening colonoscopies
 04 May 2016 
Anti-TNF therapy for IBD
 04 May 2016 
Bismuth and H. pylori eradication
 04 May 2016 
Chromoendoscopy vs colonoscopy for dysplasia in colitis
 03 May 2016 
Surgery vs medical therapy for GERD
 03 May 2016 
Vedolizumab for IBD
 03 May 2016 
PPIs and gut microbiota
 02 May 2016 
Genetic variant that increase NAFLD risk
 02 May 2016 
Resection of colorectal polyps
 02 May 2016 
Mycophenolate mofetil as first-line treatment of autoimmune hepatitis
 29 April 2016 
Crohn's disease associated genes
 29 April 2016 
Simvastatins and survival in cirrhosis
 29 April 2016 
HCV infection in Baby Boomers with Medicare

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us